Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Noven Gains Phase III Vasomotor Symptoms Candidate With JDS Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Miami firm predicts four potential new product launches in four years based on specialty pharma JDS’ pipeline.

You may also be interested in...



Nutrition 21 Revives Under Leadership Of Former Pharma Exec Satow

Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.

Nutrition 21 Revives Under Leadership Of Former Pharma Exec Satow

Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.

Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”

Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.

Related Content

Topics

UsernamePublicRestriction

Register

PS066298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel